Cullinan Reconciled Depreciation vs Selling General Administrative Analysis
CGEM Stock | USD 23.50 0.71 3.12% |
Cullinan Oncology financial indicator trend analysis is way more than just evaluating Cullinan Oncology LLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cullinan Oncology LLC is a good investment. Please check the relationship between Cullinan Oncology Reconciled Depreciation and its Selling General Administrative accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
Reconciled Depreciation vs Selling General Administrative
Reconciled Depreciation vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cullinan Oncology LLC Reconciled Depreciation account and Selling General Administrative. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Cullinan Oncology's Reconciled Depreciation and Selling General Administrative is 0.8. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Cullinan Oncology LLC, assuming nothing else is changed. The correlation between historical values of Cullinan Oncology's Reconciled Depreciation and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Cullinan Oncology LLC are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Reconciled Depreciation i.e., Cullinan Oncology's Reconciled Depreciation and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | 0.8 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Reconciled Depreciation
Selling General Administrative
Most indicators from Cullinan Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. As of the 3rd of June 2024, Selling General Administrative is likely to grow to about 44.6 M, though Tax Provision is likely to grow to (13.4 M).
2023 | 2024 (projected) | Non Recurring | 183.9K | 97.2K | Research Development | 148.2M | 155.6M |
Cullinan Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Cullinan Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cullinan Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.5M | 214.7M | 437.2M | 561.1M | 485.1M | 509.4M | |
Total Current Liabilities | 2.5M | 14.3M | 11.7M | 22.5M | 28.1M | 29.5M | |
Accounts Payable | 934K | 9.7M | 3.2M | 2.7M | 2.5M | 2.0M | |
Other Current Assets | 1.5M | 2.1M | 6.1M | 7.2M | 13.1M | 13.8M | |
Total Liab | 140.4M | 291.0M | 11.8M | 26.1M | 31.2M | 56.0M | |
Total Stockholder Equity | (40.8M) | (77.6M) | 422.6M | 535.0M | 453.7M | 476.4M | |
Net Tangible Assets | (40.8M) | (77.6M) | 425.0M | 535.0M | 615.3M | 646.0M | |
Retained Earnings | (41.5M) | (93.3M) | (158.9M) | (47.7M) | (200.9M) | (190.8M) | |
Cash | 63.3M | 168.2M | 430.9M | 550.1M | 98.4M | 147.9M | |
Total Current Assets | 100.1M | 212.3M | 296.6M | 474.5M | 480.2M | 504.2M | |
Other Current Liab | 1.6M | 4.6M | 8.6M | 18.2M | 24.2M | 25.4M | |
Property Plant And Equipment Net | 182K | 130K | 77K | 5.3M | 3.5M | 3.7M | |
Net Debt | (63.3M) | (168.2M) | (430.9M) | (544.9M) | (94.8M) | (99.6M) | |
Non Current Assets Total | 370K | 2.4M | 140.6M | 86.6M | 4.9M | 4.7M | |
Cash And Short Term Investments | 98.6M | 210.2M | 430.9M | 550.1M | 467.1M | 328.3M | |
Short Term Investments | 35.4M | 42.0M | 230.7M | 311.1M | 368.6M | 387.1M | |
Liabilities And Stockholders Equity | 100.5M | 214.7M | 434.8M | 561.1M | 485.1M | 335.6M | |
Non Current Liabilities Total | 137.8M | 276.7M | 65K | 3.6M | 3.1M | 2.9M | |
Other Stockholder Equity | (137.0M) | (261.0M) | 582.3M | 585.3M | 654.7M | 687.4M | |
Net Invested Capital | (40.8M) | (77.6M) | 425.0M | 535.2M | 453.7M | 233.7M | |
Property Plant And Equipment Gross | 182K | 130K | 309K | 5.4M | 3.9M | 4.1M | |
Accumulated Other Comprehensive Income | (4K) | (2K) | (838K) | (2.6M) | (129K) | (135.5K) | |
Net Working Capital | 97.6M | 198.0M | 284.8M | 452.0M | 452.1M | 278.2M | |
Property Plant Equipment | 182K | 130K | 77K | 1.2M | 1.4M | 1.4M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Cullinan Oncology LLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Cullinan Oncology LLC information on this page should be used as a complementary analysis to other Cullinan Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Cullinan Stock analysis
When running Cullinan Oncology's price analysis, check to measure Cullinan Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cullinan Oncology is operating at the current time. Most of Cullinan Oncology's value examination focuses on studying past and present price action to predict the probability of Cullinan Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cullinan Oncology's price. Additionally, you may evaluate how the addition of Cullinan Oncology to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Cullinan Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.